Valuation: Mymetics Corporation

Market Cap 439K 383K 361K 328K 615K 42.1M 617K 4.33M 1.67M 21.41M 1.65M 1.61M 68.87M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.89M 59.38M 53.92M 101M 6.92B 101M 711M 274M 3.52B 271M 265M 11.32B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-40.74% 45
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average +4.01%+1.48%+106,690.16%+183.96% 27.48B
Weighted average by Cap. -0.47%+1.44%+36.51%+147.97%

Financials

2021 2022
Net sales 430K 375K 354K 322K 602K 41.26M 605K 4.24M 1.64M 20.98M 1.62M 1.58M 67.5M 1.03M 896K 846K 769K 1.44M 98.64M 1.45M 10.14M 3.91M 50.15M 3.86M 3.78M 161M
Net income -4.73M -4.12M -3.89M -3.54M -6.63M -454M -6.65M -46.65M -18M -231M -17.77M -17.37M -742M -4.8M -4.19M -3.96M -3.59M -6.73M -461M -6.76M -47.39M -18.29M -234M -18.05M -17.65M -754M
Net Debt 67.1M 58.51M 55.25M 50.17M 94M 6.44B 94.39M 662M 255M 3.27B 252M 246M 10.53B 71.68M 62.51M 59.02M 53.6M 100M 6.88B 101M 707M 273M 3.5B 269M 263M 11.25B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!